Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

L. Cunningham, Anthony; Lal, Himal; Kovac, Martina; Chlíbek, Roman; Hwang, Shinn‐Jang; Díez‐Domingo, Javier; Godeaux, Olivier; J. Levin, Myron; E. McElhaney, Janet; Puig‐Barberà, Joan; Vanden Abeele, Carline; Vesikari, Timo; Watanabe, Daisuke; Zahaf, Toufik; Ahonen, Anitta; Athan, Eugene; Fernando Barba‐Gómez, José; Cámpora, Laura; de Looze, Ferdinandus; Jackson Downey, H.; Ghesquière, Wayne; Gorfinkel, Iris; Korhonen, Tiina; Leung, Edward; McNeil, Shelly; Oostvogels, Lidia; Rombo, Lars; Smetana, Jan; Yin Weckx, Lily; W Yeo, W; C. Heineman, Thomas

doi:10.1056/nejmoa1603800

Public

Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Published in New England Journal of Medicine • Sep 14, 2016

Authors:

Anthony L. Cunningham

Himal Lal

Martina Kovac

Abstract

BACKGROUND: A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01B adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associate...

Subject

Medicine

Placebo

Postherpetic neuralgia

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!